Dr. Crist is a Scientist at the NCL and Head of the lab's Strategic Client Relations section. In this role, she coordinates research efforts across multiple disciplines to promote the clinical translation of novel nanotech therapeutics and diagnostics for cancer, and most recently Sars-CoV-2. With more than a decade of experience in the nanotech field, she has managed more than a hundred interdisciplinary scientific collaborations with academic and pharmaceutical organizations from around the globe, developing an extensive network of the world's leading experts in nanomedicine. She has also interfaced with various agencies within the US Government with respect to regulatory and consumer safety aspects of nanotechnology and served as an Executive Board member for the European Union’s Nanomedicine Characterization consortia. In addition, she holds memberships with ASTM International and the Regulatory Affairs Professional Society.
Prior to joining the NCL in 2009, Dr. Crist completed a post-doctoral fellowship with the HIV Drug Resistance Program, National Cancer Institute at Frederick. She received her Ph.D. degree in chemistry from Michigan State University and her B.S. degree in chemistry from Miami University. Her research experiences include molecular biology, protein and virology techniques, and organic synthesis.